🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For patients with #btcsm, every opportunity to plan for the future is cherished. If you are at #ESMOGI25 please see my #OncoAlertAF colleague Erman Akkus poster. #Ferritin is a readily accessible biomarker with important prognostic implications #GIonc Myriam Chalabi Dr. Cathy Eng

🙌 #ESMOGI25 has begun — in Barcelona, and online! Join the global community advancing GI cancer research & treatment from 2–5 July. Let’s make an impact! 🔗 ow.ly/Y6x750WgS01

Can we expand how we tx #HCC?? #ESMOGI25 data suggests we can! 🔑 points: - SIERRA: CP-B7/8, PS 2, or PVT tx’ed STRIDE safely ➡️ more #’s may help, but ✅ - ABSK-011-201: FGF19+ naive AND pre-tx, impressive ORR, but mainly Hep B pts, 🤔 applicability #ESMOAmbassadors ESMO - Eur. Oncology

#ESMOGI25 🚨: Claudin 18.2 bispecific plus nivo/FOLFOX in Claudin 18.2 + #UpperGI cancers! 🔑 points: - ORR 71%, 6 mth PFS 72.9% - Response regardless of PDL-1 CPS - broader defn of Claudin + makes this relevant to larger population - no DLTs noted. #ESMOAmbassadors ESMO - Eur. Oncology

Incredible opportunities for #YoungOncologists at #ESMOGI25! Don’t miss learning from the experts! ✨🌟 ESMO - Eur. Oncology #ESMOAmbassadors

Excellent summary for intermediate stage #HCC by Tanios Bekaii-Saab, MD! Progress but many ❓🤨: - Is PFS the right endpoint? - TACE vs TARE - Sequence vs concurrent #ESMOGI25 #ESMOAmbassadors ESMO - Eur. Oncology

Beyond PDL1 for #HCC - great overview by Dr. Stephen Chan. 🔑 takeaways: - Multiple novel 🎯 - cell therapies coming 🥳 - T cell engagers 🧐 #ESMOGI25 #ESMOAmbassadors ESMO - Eur. Oncology

#ESMOGI25 orals: MATTERHORN PROs are here 👏: - PRO compliance rate high ✅ - No decline in QOL with FLOT + D - Anxiety 📉 after therapy #ESMOAmbassadors ESMO - Eur. Oncology Salah-Eddin Al-Batran

#ESMOGI25 orals: PANOVA-3 QOL is out ‼️ Teresa Macarulla - ⬆️ global QOL - ⬇️ time to deterioration for pain - ⬇️ opioid use TTF needing to be worn 18 hrs/day ⁉️ ESMO - Eur. Oncology #ESMOAmbassadors

#ESMOGI25 orals: CM 8HW QOL - Nivo/Ipi in MSI-H/dMMR #CRC - No ⬇️ in HrQOL - Given known potential tox, reassuring data ESMO - Eur. Oncology #ESMOAmbassadors

#ESMOGI25 orals: TALENTACE, TACE plus Atezo/Bev in intermediate to high tumor burden #HCC - ⬆️ TACE-PFS 11.3 vs 7 mths - ORR 49 vs 34% - OS immature #ESMOAmbassadors ESMO - Eur. Oncology

#ESMOGI25 orals: CM 9DW QOL in #HCC ESMO - Eur. Oncology #ESMOAmbassadors - Nivo/Ipi with ⬇️ HrQOL deterioration - PROs show less bother from side effects with Nivo/Ipi - No negative impact of TRAE related 🛑 on efficacy

#ESMOGI25 orals: as always, Lorenza Rimassa puts it all in perspective 😎 #ESMOAmbassadors ESMO - Eur. Oncology

And that’s a wrap on #ESMOGI in vibrant Barcelona! Honored to chair the #KRAS in pancreatic cancer symposium, present the COMBAT-Pancreatic Cancer trial, and reconnect with amazing colleagues. Until next time—Adios Barcelona! 🇪🇸 Rachna Shroff, MD, MS, FASCO

🙋‍♀️Hello!! How's your schedule this fall? 🌟#WomenInOncology, save Sep 27-28 for #LEAD25! It's a fantastic opportunity for career development, networking with many inspiring and impactful women in oncology! 👉 bioascend.com/lead/ Dr. Julie Brahmer Ana I. Velázquez Mañana, MD, MSc, FASCO Dr. Catherine Lai

Top Oncologists from ESMO - Eur. Oncology Gastrointestinal (GI) Cancers Annual Congress 2025 Explore more #ESMOGI25 insights and data: t.ly/kXH8X #LARVOL #GICancer #GastrointestinalCancer #Oncology #CancerResearch #CancerData #ClinicalTrials #OncologyInsights | Angela Lamarca

Top Women Oncologists from ESMO - Eur. Oncology Gastrointestinal (GI) Cancers Annual Congress 2025 Explore more #ESMOGI25 insights and data: t.ly/kXH8X #LARVOL #GICancer #GastrointestinalCancer #Oncology #CancerResearch #CancerData #ClinicalTrials #OncologyInsights |

The Top Most Active Cancer Institutes that were leading the conversation during ESMO - Eur. Oncology Gastrointestinal (GI) Cancers Annual Congress 2025, ranked based on oncologists' reactions and engagement on X. Explore more #ESMOGI25 insights and data: t.ly/kXH8X #LARVOL

25 Posts Not To Miss From ESMO GI 2025 ESMO - Eur. Oncology Amalya Sargsyan Myriam Chalabi Rachna Shroff, MD, MS, FASCO Erman Akkus Dr. Cathy Eng Teresa Macarulla DrJorgeB_George Lorenza Rimassa Angela Lamarca Arndt Vogel oncodaily.com/societies/25-p… #Cancer #Oncology #OncoDaily #Health #Medicine

Now THIS is out of office…